Year archive

Medivir — 2012 filings

All 51 regulatory filings released by Medivir (MVIR) in 2012, sourced directly from the official regulator.

51 Filings

2012 Period

2012 filings (51)

Filing	Released	Lang
Medivir announces phase III data for Simeprevir demonstrating efficacy and safety in genotype 1 hepatitis C patients Earnings Release FY 2012	2012-12-20	English
Medivir meddelar Simeprevir fas III-resultat, som visar effekt och säkerhet i hepatit C-patienter av genotyp 1 Earnings Release FY 2012	2012-12-20	Swedish
Medivir meddelar att del två av den interferonfria fas II-studien med Simeprevir och sofosbuvir för behandling av hepatit C inletts Legal Proceedings Report	2012-12-13	Swedish
Medivir announces initiation of the second cohort of the interferon-free phase II study combining Simeprevir and sofosbuvir for hepatitis C treatment Legal Proceedings Report	2012-12-13	English
Interim / Quarterly Report 2012 Interim / Quarterly Report 9M 2012	2012-11-20	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report 9M 2012	2012-11-20	English
Medivir meddelar att Janssen och Vertex planerar att genomföra en oral fas II-studie med simeprevir (TMC435) och VX-135 för behandling av hepatit C Regulatory Filings	2012-11-01	Swedish
Medivir announces a phase II all-oral study of Simeprevir (TMC435) and VX-135 for the treatment of Hepatitis C to be conducted by Janssen and Vertex Earnings Release FY 2012	2012-11-01	English
Medivir announces that Simeprevir (TMC435) data will be presented at the upcoming AASLD Meeting Report Publication Announcement	2012-10-01	English
Medivir meddelar att data för Simeprevir (TMC435) kommer presenteras på den internationella leverkongressen AASLD Regulatory Filings	2012-10-01	Swedish
A phase IIa interferon free combination hepatitis C trial of Simeprevir (TMC435) and TMC647055 will commence shortly Investor Presentation	2012-09-20	English
En interferonfri fas IIa kombinationsstudie med simeprevir (TMC435) och TMC647055 för behandling av hepatit C kommer att inledas inom kort Investor Presentation	2012-09-20	Swedish
Medivir förvärvar prekliniska forskningsprogram inom det antivirala området, bland annat mot hepatit C, samt ”prodrug”-teknologier M&A Activity	2012-09-05	Swedish
Medivir acquires preclinical antiviral programs including hepatitis C and prodrug technologies M&A Activity	2012-09-05	English
Interim / Quarterly Report 2012 Interim / Quarterly Report H2 2012	2012-08-23	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report H1 2012	2012-08-23	English
Klinisk fas Ia-studie med MIV-711 avslutad och fas Ib-studie inledd Legal Proceedings Report	2012-08-21	Swedish
Clinical phase Ia trial on MIV-711 complete and phase Ib trial commences Regulatory Filings	2012-08-21	English
Major Shareholding Notification 2012 Major Shareholding Notification	2012-07-04	English
Medivir meddelar att en interferonfri fas II-studie med TMC435 i kombination med daclatasvir kommer att inledas inom kort Regulatory Filings	2012-06-29	Swedish
Medivir announces an interferon-free phase II combination trial with TMC435 and daclatasvir to commence shortly Regulatory Filings	2012-06-29	English
Medivir initiates collaboration with Swedish University of Agricultural Sciences to develop new drugs for bacterial infections Regulatory Filings	2012-06-26	English
Medivir inleder ett samarbete med Sveriges Lantbruksuniversitet för att utveckla nya läkemedel mot bakterieinfektioner Regulatory Filings	2012-06-26	Swedish
Antal aktier och röster i Medivir Declaration of Voting Results & Voting Rights Announcements	2012-05-31	Swedish
Number of shares and votes in Medivir Share Issue/Capital Change	2012-05-31	English
Medivir has initiated a phase I clinical trial with its cathepsin K inhibitor MIV-711 Regulatory Filings	2012-05-28	English
Medivir inleder klinisk fas I-studie med sin cathepsin K-hämmare MIV-711 Legal Proceedings Report	2012-05-28	Swedish
Ny kommersiellt ansvarig utnämnd Board/Management Information	2012-05-15	Swedish
New Executive Vice President Commercial appointed Board/Management Information	2012-05-15	English
Resolutions at the annual general meetings in Medivir on 10 May 2012 AGM Information	2012-05-10	English
Beslut vid årsstämma i Medivir den 10 maj 2012 AGM Information	2012-05-10	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report Q1 2012	2012-05-10	Swedish
Interim / Quarterly Report 2012 Interim / Quarterly Report Q1 2012	2012-05-10	English
Medivir announces TMC435 in an expanded clinical collaboration Regulatory Filings	2012-04-18	English
Medivir offentliggör utvidgat kliniskt samarbete för TMC435 Investor Presentation	2012-04-18	Swedish
Annual Report 2011 Annual Report FY 2011	2012-04-10	Swedish
Annual Report 2011 Annual Report FY 2011	2012-04-10	English
Årsredovisning 2011 Report Publication Announcement	2012-04-10	Swedish
Annual Report 2011 Report Publication Announcement	2012-04-10	English
Medivir tillkännager att fyra TMC435-abstrakt accepterats för presentation på EASL-mötet Regulatory Filings	2012-04-04	Swedish
Medivir Announces Acceptance of Four TMC435 Abstracts for Presentation at the EASL meeting Regulatory Filings	2012-04-04	English
Ansökan att starta fas I prövningar med cathepsin K inlämnad till myndigheter Regulatory Filings	2012-03-19	Swedish
Application to start phase I trials with cathepsin K filed with authorities Regulatory Filings	2012-03-19	English
Medivir announces new studies in phase III program for TMC435 Investor Presentation	2012-03-13	English
Medivir offentliggör nya studier i fas III-programmet för TMC435 Regulatory Filings	2012-03-13	Swedish
Interim / Quarterly Report 2011 Interim / Quarterly Report FY 2011	2012-02-23	Swedish
Earnings Release 2011 Earnings Release FY 2011	2012-02-23	English
Valberedningens förslag till ny styrelse inför årsstämman 2012 Board/Management Information	2012-02-16	Swedish
Nomination Committee proposal for the Board for the 2012 Annual General Meeting AGM Information	2012-02-16	English
Medivir’s partner GSK initiates OTC launch of Xerclear® in Europe under trade names Zoviduo and Zovirax Duo Regulatory Filings	2012-02-08	English
Medivirs partner GSK har startat sin OTC-lansering av Xerclear® i Europa under varunamnen Zoviduo och Zovirax Duo Regulatory Filings	2012-02-08	Swedish

Filings by year

2026 19 filings
2025 39 filings
2024 32 filings
2023 33 filings
2022 15 filings
2021 52 filings
2020 28 filings
2019 19 filings
2018 57 filings
2017 52 filings
2016 59 filings
2015 70 filings
2014 76 filings
2013 93 filings
2012 51 filings
2011 79 filings
2010 78 filings
2009 45 filings
2008 40 filings
2007 26 filings